Inhibition of endothelial nitric oxide synthase in cholangiocarcinoma cell lines – a new strategy for therapy

Manida Suksawat1,2, Anchalee Techasen2,3,4, Nisana Namwat1,2,4, Thianrut Boonsong4,5, Attapol Titapun2,4,5, Piti Ungarreevittaya2,4,6, Puangrat Yongvanit2,4 and Watcharin Loilome1,2,4

1 Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Thailand
2 Cholangiocarcinoma Research Institute, Khon Kaen University, Thailand
3 Faculty of Associated Medical Science, Khon Kaen University, Thailand
4 Cholangiocarcinoma Screening and Care Program (CASCAP), Khon Kaen University, Thailand
5 Department of Surgery, Faculty of Medicine, Khon Kaen University, Thailand
6 Department of Pathology, Faculty of Medicine, Khon Kaen University, Thailand

Keywords
cholangiocarcinoma; eNOS; invasion; metastasis; migration

Correspondence
W. Loilome, Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
Tel: +66-043-348386
E-mail: watloi@yahoo.com

(Received 6 August 2017, revised 14 December 2017, accepted 1 January 2018)
doi:10.1002/2211-5463.12388

The isoform of nitric oxide synthase (NOS) found in endothelial cells (eNOS) plays a crucial role in vasodilation. We recently reported the activation of eNOS in cholangiocarcinoma (CCA) tissues and cell lines. Moreover, we also reported that the abundance of eNOS and phosphorylated eNOS (p-eNOS), as well as its upstream regulator proteins, is significantly associated with the metastatic status of CCA patients. However, the function of eNOS in CCA progression has not been addressed. Therefore, the present study aimed to investigate the function of eNOS involved in the migration and invasion ability of CCA cell lines. The results reveal that eNOS activation significantly increases migration and invasion ability of CCA cells via the up-regulation of phosphorylated vasodilator-stimulated protein (p-VASP). A combination treatment with recombinant human vascular endothelial growth factor C and eNOS inhibitor (N-nitro-L-arginine methyl ester hydrochloride) resulted in the down-regulation of p-VASP, as well as a decreased migration and invasion ability of the CCA cell line. Thus, this work suggests that eNOS can serve as an attractive target to inhibit the progression of CCA.

Cholangiocarcinoma (CCA) is an invasive cancer that originates from the bile duct epithelium. It has a high incidence and has been recognized as a major public health problem in the northeastern part of Thailand [1]. The development and pathogenesis of CCA is associated with liver fluke (Opisthorchis viverrini; Ov) infection resulting in chronic inflammation of bile duct. This is recognized as the major risk factor for CCA development in this region [2,3]. In addition, the alteration of genes and proteins involved in the kinase pathway can promote CCA cell growth and migration [4–10].

We previously found that multiple protein kinases, including membrane receptor tyrosine kinases and cytoplasmic kinases, are over-activated in CCA. Among the activated proteins, endothelial nitric oxide synthase (eNOS) phosphorylated at serine 1177 (p-eNOS (Ser1177)) was found to be overactivated in both CCA cell lines and CCA tissues. Beside eNOS, vascular endothelial growth factor receptor (VEGFR) 3 was

Abbreviations
CCA, cholangiocarcinoma; eNOS, endothelial nitric oxide synthase; IL-18, interleukin-18; iNOS, inducible nitric oxide synthase; l-NAME, N-nitro-L-arginine methyl ester hydrochloride; nNOS, neuronal nitric oxide synthase; NO, nitric oxide; NOS, nitric oxide synthase; Ov, Opisthorchis viverrini; PI3K, phosphoinositide-3-kinase; rhVEGF-C, recombinant human vascular endothelial growth factor C; VASP, vasodilator-stimulated protein; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.
Targeting eNOS inhibits CCA cells

M. Suksawat et al.

also found activated in CCA cell lines and tissues [4]. VEGFR3 has vascular endothelial growth factor (VEGF) C and D as its specific ligands. However, based on our review the axis of VEGF-C–VEGFR3 is more strongly associated with eNOS and cancer progression than is VEGF-D. In addition, we reported the association of eNOS with VEGF-C and VEGFR3, which can act as upstream regulators of eNOS. We also demonstrated that the abundance of eNOS, p-eNOS (Ser1177) and its upstream regulator proteins, VEGF-C and VEGFR, was associated with the metastatic status of CCA patients. Interestingly, the co-high-expression of eNOS/p-eNOS and its upstream regulators also significantly correlated with metastasis in CCA patients [11]. These results convinced us to focus on the role of eNOS in the migration and invasion ability in an in vitro CCA model.

The nitric oxide (NO)-generating enzyme nitric oxide synthase (NOS) has three isoforms: neuronal (nNOS), inducible (iNOS) and endothelial (eNOS) [12]. Normally, eNOS is mainly found in endothelial cells where it plays an important role in vascular relaxation [13]. eNOS also plays roles in pathological processes, including cancer development [14–16]. It has been detected in various types of cancer [17,18], where it is involved in carcinogenesis, including cell proliferation in oral squamous cancer cell lines [19] and antiapoptosis in prostate cancer cells [18]. Moreover, eNOS is involved in angiogenic processes in gastric cancer [20] and promotes invasion and metastasis in mammary cancer cells [21]. eNOS is strongly regulated by VEGF through the phosphoinositide-3-kinase (PI3K)–Akt pathway [22] resulting in p-eNOS (Ser1177) and an increase in NO production [23]. Interestingly, a high level of activation of the VEGFR3 and PI3K–Akt pathway has been found also in CCA [4,10]. Thus, the inhibition of eNOS may act as a therapeutic strategy to inhibit cancer progression, potentially via the use of L-nitro- l-arginine methyl ester hydrochloride (l-NAME), an l-arginine analogue that is an eNOS inhibitor. l-NAME is approximately 10 times more specific for eNOS than for iNOS, and is widely used to inhibit eNOS activity in many types of cancer [24].

In the present study we explored the function of eNOS in CCA migration and invasion. The induction of eNOS activation was performed by human recombinant VEGF-C (rhVEGF-C) in combination with l-NAME, an eNOS inhibitor. In addition, the molecular mechanism by which eNOS regulates CCA cell migration and invasion was demonstrated.

Materials and methods

Human CCA cell lines and cell culture

Human CCA cell line KKU-213 was purchase from the JCRB cell bank. The cell line was cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum, 44 mM NaHCO₃, penicillin (100 units·mL⁻¹) and streptomycin (100 mg·mL⁻¹) (Thermo Fisher Scientific), and the cell line was grown in a humidified atmosphere at 37 °C containing 5% CO₂.

Antibodies

Primary antibodies were used in this study, including anti-eNOS, which was purchased from BD Bioscience (San Jose, CA, USA), and p-eNOS purchased from Abcam (Cambridge, MA, USA). rhVEGF-C was reconstituted in sterile PBS at a stock concentration of 10⁵ ng·mL⁻¹ and stored at −20 °C until used. The inhibitor of eNOS, l-NAME, was purchased from Sigma-Aldrich (St Louis, MO, USA).

Recombinant human VEGF-C and eNOS inhibitor

The recombinant human VEGF-C (rhVEGF-C) cys156ser, which is specific for VEGFR3, was purchased from R&D system (Minneapolis, MN, USA). rhVEGF-C was reconstituted in sterile PBS at a stock concentration of 10⁵ ng·mL⁻¹ and stored at −20 °C until used. The inhibi-
Oberkochen, Germany). After detection, the quantification of immunofluorescence density was performed with ImageJ and calculated following the formula:

Corrected total cell fluorescence = Integrated density – (Area of selected cell × Mean fluorescence of background readings). This quantification method followed from previous publications [25,26].

**Western blot analysis**

Cells were treated with 100 ng·mL⁻¹ rhVEGF-C and the combination of 100 ng·mL⁻¹ rhVEGF-C and different concentrations of l-NAME (1, 10 and 100 μM) for 24 h. Cell lysates were electrophoresed and transferred to a poly (vinylidene) difluoride membrane (Millipore, Billerica, MA, USA). This was blocked with 5% skim milk in Tris-buffered saline (TBS) at room temperature for 1 h and incubated with primary antibody at 4 °C overnight. After that, it was rinsed with TBS containing 0.1% polyoxyethylene-sorbitan monolaurate (Tween-20; TBST) followed by incubation with horseradish peroxidase-conjugated secondary antibody from Santa Cruz Biotechnology (Dallas, TX, USA) at room temperature for 1 h. The membranes were rinsed with TBST and exposed to ECL Prime Western Blotting Detection System (GE Healthcare Bio-Sciences, Little Chalfont, UK). The immunoblot and intensity were analyzed with the ImageQuant™ analysis system (GE Healthcare Bio-Sciences). Human β-actin served as the loading control.

**Migration assay**

A cell migration assay was performed using a Boyden chamber transwell consisting of a membrane filter insert in 24-well plates, 8 μm pore size (Corning, New York, USA). The KKU-213 (4 × 10⁴ cells) cell line was pretreated with 100 ng·mL⁻¹ of rhVEGF-C and the combination of 100 ng·mL⁻¹ rhVEGF-C and different concentrations of l-NAME (1, 10 and 100 μM) for 30 min before seeding into the upper chamber with serum free medium. The lower chamber contained complete medium and was incubated for 24 h. After 24 h, non-migrating cells in the upper chamber were removed. Migrating cells that attached at the underside of the filter were fixed with ethanol for 1 h and stained overnight with hematoxylin. Quantification of the migrating cells was performed by counting under a light microscope (×20 magnification). The experiments were carried out in duplicate and two independent experiments were repeated.

**Invasion assay**

A Boyden chamber with an insert filter coated with Matrigel, 8-μm pore size (Corning), was used for the invasion assay. The assay kit was reconstituted by placing serum-free medium into the upper chamber and complete medium into the lower chamber for approximately 1 h. At the same time, KKU-213 (4 × 10⁴) cells were pretreated with 100 ng·mL⁻¹ of rhVEGF-C and the combination of 100 ng·mL⁻¹ rhVEGF-C and different concentrations of l-NAME (1, 10 and 100 μM) for 30 min. Before seeding the pretreated cells, serum-free medium was removed and replaced with the pretreated cells in the upper chamber. After 24 h, non-invading cells that were found in the upper filter were removed. Invading cells that attached under the filter were fixed with ethanol for 1 h followed by staining overnight with hematoxylin. The quantification of invading cells was performed by counting under a light microscope (×20 magnification). The experiments were carried out in duplicate and two independent experiments were repeated.

**Statistical analysis**

Statistical analyses were performed with SPSS Statistics version 17 (SPSS Inc., Chicago, IL, USA). The difference between groups was expressed as a mean ± SD and analyzed by Student’s *t* test. A *P*-value less than 0.05 was considered statistically significant.

**Results**

**rhVEGF-C induced expression level of p-eNOS**

In our previous report, we demonstrated that VEGF-C can act as a specific upstream regulator of eNOS in the CCA model [11]. Therefore, we further explored the role of VEGF-C in the regulation of eNOS, as well as in the migration and invasion phenotypes of the CCA cell line. We treated the CCA cell line with rhVEGF-C at different concentrations and observed the level of p-eNOS (Fig. 1A). The level of p-eNOS was significantly increased in a dose-dependent manner when compared with the untreated control (*P* = 0.019, 0.002 and 0.003, respectively). However, a concentration of 200 ng·mL⁻¹ of rhVEGF-C caused a slight decrease in the level of p-eNOS (Fig. 1B). A concentration of 100 ng·mL⁻¹ of rhVEGF-C caused the highest increase of p-eNOS in CCA cells.

**rhVEGF-C induced CCA cell migration**

Our previous report demonstrated the strong correlation of the expression of eNOS, p-eNOS and VEGF-C with the metastatic status of CCA patients [11]. Thus we evaluated the migration phenotype of CCA cell lines that were treated with different concentrations of rhVEGF-C. Interestingly, a significant increase in cell migration was observed in CCA cells that were treated with 100 ng·mL⁻¹ of rhVEGF-C when compared with
the untreated control cells ($P = 0.001$) (Fig. 2), whereas migration decreased at 200 ng/mL, at which concentration a decrease in the level of p-eNOS was observed.

**rhVEGF-C induced CCA cell migration through the activation of eNOS**

We further explored whether rhVEGF-C-induced CCA cell migration was caused, at least in part, by activation of eNOS. We induced CCA cell migration by using rhVEGF-C in combination with different concentrations of l-NAME, an eNOS inhibitor, which has no effect on the growth of CCA cell lines (Fig. S1). The result indicated that the migration ability of the CCA cell line is significantly increased when treated with rhVEGF-C compared with the control ($P < 0.001$). Interestingly, a dramatic decrease in CCA cell migration was seen when l-NAME was combined in a dose-dependent manner ($P < 0.001$ in all groups; Fig. 3). Our data confirm that rhVEGF-C induces CCA cell migration through the activation of eNOS.

**rhVEGF-C induced CCA cell invasion through the activation of eNOS**

We also explored the function of eNOS in the invasion by CCA. CCA cells were treated with rhVEGF-C in combination with different concentrations of l-NAME after which cell invasion ability was observed. rhVEGF-C treatment can cause a significant increase in CCA cell invasion when compared with the
untreated control cells ($P < 0.001$). On the other hand, the combination of rhVEGF-C and 1-NAME caused a dramatic decrease of CCA cell invasion in a concentration-dependent manner ($P < 0.001$ in all groups; Fig. 4). In summary, activation of eNOS is involved in CCA cell invasion.
**L-NAME suppresses CCA cell migration and invasion via an inhibition of Akt, eNOS and VASP activation**

Next, we explored the molecular mechanism by which eNOS is involved in CCA progression. Immunolabeling was used to detect the expression of eNOS (Fig. 5A,C), while immunoblotting was used to detect the expression of the protein kinases PI3K, p-Akt and Akt. The protein kinase Akt directly phosphorylated eNOS at Ser1177. Then, the VASP protein, which is the downstream effector of eNOS, was activated and phosphorylated at Ser239 (Fig. 5E). The results revealed that rhVEGF-C treatment significantly increases the expression of eNOS and p-eNOS ($P < 0.001$ and $P = 0.035$, respectively) (Fig. 5B,D), and could slightly increase the expression of PI3K, p-Akt and p-VASP (Fig. 5F–H). In contrast, the combination treatment of rhVEGF-C with L-NAME decreased the expression of p-eNOS, eNOS, p-Akt and p-VASP in a concentration-dependent manner (Fig. 5B,D,G and H, respectively). In particular, the combination of rhVEGF-C with 10 and 100 μM L-NAME showed significant decreases in the expression level of p-eNOS ($P = 0.013$ and $P = 0.0045$ for 10 and 100 μM, respectively). The combination treatment of rhVEGF-C and L-NAME not only inhibited the expression level of p-eNOS, eNOS and p-VASP, but also significantly inhibited the expression level of p-Akt at all concentrations ($P = 0.044$, 0.022 and 0.049 for 1, 10 and 100 μM L-NAME, respectively).

Summarizing, eNOS is stimulated via the VEGF-C–PI3K–Akt pathway resulting in an increase in the migration and invasion of the CCA cell line through the up-regulation of p-VASP expression. Conversely, the inhibition of eNOS by L-NAME resulted in a decrease in the migration and invasion abilities of the CCA cell line by suppressing the activation of expression of p-VASP. The inhibition of eNOS by L-NAME might act as a negative feedback loop to inhibit the expression level of p-Akt.

**Discussion**

NOS is a nitric oxide generating enzyme with three isoforms: nNOS, iNOS and eNOS. The expression of eNOS occurs mainly in endothelial cells where it promotes the relaxation of vessels through the release of NO [27]. However, eNOS is also expressed in several cancer types [18,20,28], where it plays a role in cell proliferation, antiapoptosis, angiogenesis, invasion and metastasis [29]. The regulation of eNOS is dependent on several upstream regulator proteins [27,30,31].
Fig. 5. (A) Level of expression of p-eNOS in each experimental group. DAPI, 4′,6-diamidino-2-phenylindole. (B) Corresponding graph of the level of expression of p-eNOS. (C,D) Level of expression of eNOS (C) with the corresponding graph (D). (E) Immunoblot of the signaling molecules that are involved in eNOS activation and inhibition. Actin was used as loading control. (F–H) Level of expression of PI3K, p-Akt and p-VASP, respectively. Scale bar = 50 μm. *P < 0.05; **P < 0.005; ***P < 0.0005.
among which VEGF-C and its specific receptor, VEGFR3, have been strongly associated with the expression and activation of eNOS [22]. The alteration of receptor tyrosine kinases and their downstream kinase proteins involved in the development of CCA have been identified. Among the downstream kinases, enhanced expression of eNOS is seen in both CCA cell lines and CCA tissues, with VEGFR3 also being activated [4]. The expression of eNOS, p-eNOS, VEGF-C and VEGFR3 is significantly associated with metastasis in CCA patients. In addition, the co-high-expression of eNOS with its specific upstream regulator proteins, VEGF-C and VEGFR3, is also significantly associated with metastasis in CCA patients [11]. This suggests that eNOS is involved in cancer metastatic processes, especially when VEGF-C/VEGFR3 is present. This study aimed to explore the function of eNOS in the metastatic process in a CCA cell line upon activation by rhVEGF-C and inhibition by eNOS inhibitor. Thus, inhibition of eNOS by L-NAME can serve as a possible strategy to inhibit CCA progression.

Our results show that at a rhVEGF-C concentration of 100 ng·mL⁻¹ there was a significantly increased expression of p-eNOS and CCA cell migration. In contrast, a high dose of 200 ng·mL⁻¹ rhVEGF-C slightly decreased both the expression of p-eNOS and CCA cell migration. It is not clear why the reverse effect occurs at high doses of rhVEGF-C. However, a previous study showed a similar result. In that study, gastric cancer cells were treated with rhVEGF and the concentration measured of interleukin-18 (IL-18), which is involved in enhanced cell migration. The rhVEGF increased the concentration of IL-18 in a dose-dependent manner, but at 200 ng·mL⁻¹ of rhVEGF there was a slight decrease in the IL-18 concentration. The significant increase in CCA cell migration is consistent with a previous study involving lung cancer cells [32]. Interestingly, a combination of rhVEGF-C and L-NAME dramatically decreased CCA cell migration ability in a concentration-dependent manner. That L-NAME treatment inhibits cancer cell migration has also been found in breast cancer cells in which L-NAME inhibits 4T1 migration in a dose-dependent manner [33]. It also inhibits the migration of human colorectal cancer cells [34]. We demonstrate here for the first time that rhVEGF-C-mediated CCA migration is modulated, at least in part, by eNOS activation. In addition, the present study demonstrates that rhVEGF-C treatment significantly increases CCA cell invasion when compared with the control cells, while L-NAME inhibited this rhVEGF-C-mediated CCA cell invasion ability. Our results are supported by experiments using lung cancer cells, which demonstrated the rhVEGF-C treatment significantly increased lung cancer cell invasion [32]. Moreover, L-NAME treatment was shown to inhibit human colorectal cancer cell line invasion [34]. Although L-NAME could benefit cancer therapy, the management of the ensuing hypertension, as a side effect, needs to be considered. In a pre-clinical study, increasing hypertension was observed in an in vivo model of pancreatic ductal adenocarcinoma. However, when L-NAME was provided in combination with amlodipine, an antihypertensive drug, the blood pressure significantly decreased with no effect on the antitumor activity of L-NAME [17]. Furthermore, the molecular mechanism by which eNOS is involved in CCA cell migration and invasion were explored. The results of immunoblotting and immunolabeling indicated that rhVEGF-C activates eNOS via the PI3K–Akt pathway, which directly phosphorylates eNOS to form p-eNOS (Ser1177). This conforms with our phosphokinase array result [22,23,30]. The activation of eNOS increases cell migration and invasion through increasing the expression of p-VASP (Ser239), downstream of eNOS, which is involved in actin filament formation in cancer cells. The increase of p-VASP (Ser239) expression has also been reported to play a role in cancer cell migration and invasion in various cancer types [35,36]. Our results, show an increased expression of p-VASP in conditions of eNOS activation and a decreased expression of p-VASP in conditions of eNOS inhibition in a dose-dependent manner. Therefore, the inhibition of eNOS directly affects cancer cell migration and invasion via a decrease in the level of p-VASP (Ser239). Under conditions of L-NAME treatment, our results indicate that L-NAME can also suppress the expression of p-Akt. Similarly, some other studies have reported that the inhibition of eNOS also affects the PI3K–Akt pathway in turn to decrease expression level [37,38].

Conclusion
The abundant expression of eNOS and its upstream regulator, the VEGF family, were seen in not only CCA cell lines but also human CCA tissues. Moreover, the abundant expression of eNOS as well as its upstream regulator was also found to be significantly correlated with the metastasis status of CCA patients. However, the function of eNOS-mediated metastasis of CCA not has been established. Thus, this study presented evidence that showed eNOS induced the migration and invasion of a CCA cell line by the induction of rhVEGF-C. Interestingly, the inhibition of eNOS...
Increased EphB2 expression predicts cholangiocarcinoma metastasis. Tumour Biol 35, 10031–10041.
7 Loilome W, Bungkanjana P, Techasen A, Namwat N, Yongvanit P, Puapairoj A, Khuntikeo N and Riggins GJ (2014) Activated macrophages promote Wnt/beta-catenin signaling in cholangiocarcinoma cells. Tumour Biol 35, 5357–5367.
8 Loilome W, Juntana S, Namwat N, Bhudhisawasdi V, Puapairoj A, Sripta B, Miwa M, Saya H, Riggins GJ and Yongvanit P (2011) PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma. Int J Cancer 129, 34–44.
9 Loilome W, Yongvanit P, Wongkham C, Tepsiri N, Sripta B, Sithithaworn P, Hanai S and Miwa M (2006) Altered gene expression in Opisthorchis viverrini-associated cholangiocarcinoma in hamster model. Mol Carcinog 45, 279–287.
10 Yoithaisong S, Dokduang H, Techasen A, Namwat N, Yongvanit P, Bhudhisawasdi V, Puapairoj A, Riggins GJ and Loilome W (2013) Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol 34, 3637–3648.
11 Suksawat M, Techasen A, Namwat N, Yongvanit P, Khuntikeo N, Titapun A, Koonmee S and Loilome W (2016) Upregulation of endothelial nitric oxide synthase (eNOS) and its upstream regulators in Opisthorchis viverrini associated cholangiocarcinoma and its clinical significance. Parasitol Int 66, 486–493.
12 Govers R and Rabelink TJ (2001) Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 280, F193–F206.
13 Ortiz PA and Garvin JL (2003) Trafficking and activation of eNOS in epithelial cells. Acta Physiol Scand 179, 107–114.
14 Forstermann U and Sessa WC (2012) Nitric oxide synthases: regulation and function. Eur Heart J 33, 829–837. 837a–837d
15 Fukumura D, Kashiwagi S and Jain RK (2006) The role of nitric oxide in tumour progression. Nat Rev Cancer 6, 521–534.
16 Xu W, Liu LZ, Loizidou M, Ahmed M and Charles IG (2002) The role of nitric oxide in cancer. Cell Res 12, 311–320.
17 Lampson BL, Kendall SD, Ancrile BB, Morrison MM, Shealy MJ, Barrientos KS, Crowe MS, Kashatus DF, White RR, Gurley SB et al. (2012) Targeting eNOS in pancreatic cancer. Cancer Res 72, 4472–4482.
18 Tong X and Li H (2004) eNOS protects prostate cancer cells from TRAIL-induced apoptosis. Cancer Lett 210, 63–71.
19 Shang ZJ, Li ZB and Li JR (2006) In vitro effects of nitric oxide synthase inhibitor L-NAME on oral...
squamous cell carcinoma: a preliminary study. *Int J Oral Maxillofac Surg* **35**, 539–543.

20 Wang L, Shi GG, Yao JC, Gong W, Wei D, Wu TT, Ajani JA, Huang S and Xie K (2005) Expression of endothelial nitric oxide synthase correlates with the angiogenic phenotype of and predicts poor prognosis in human gastric cancer. *Gastric Cancer* **8**, 18–28.

21 Tu YT, Tao J, Liu YQ, Li Y, Huang CZ, Zhang XB and Lin Y (2006) Expression of endothelial nitric oxide synthase and vascular endothelial growth factor in human malignant melanoma and their relation to angiogenesis. *Clin Exp Dermatol* **31**, 413–418.

22 Lahdenranta J, Hagendoorn J, Padera TP, Hoshida T, Nelson G, Kashiwagi S, Jain RK and Fukumura D (2009) Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis. *Cancer Res* **69**, 2801–2808.

23 Michell BJ, Griffiths JE, Mitchellhill KL, Rodriguez-Crespo I, Tiganis T, Bozinovski S, de Montellano PR, Kemp BE and Pearson RB (1999) The Akt kinase signals directly to endothelial nitric oxide synthase. *Curr Biol* **9**, 845–848.

24 Alderton WK, Cooper CE and Knowles RG (2001) Nitric oxide synthases: structure, function and inhibition. *Biochem J* **357**, 593–615.

25 Burgess A, Vigneron S, Brioudes E, Labbe JC, Lorca T and Castro A (2010) Loss of human Greatwall results in G2 arrest and multiple mitotic defects due to deregulation of the cyclin B-Cdc2/PP2A balance. *Proc Natl Acad Sci USA* **107**, 12564–12569.

26 McCloy RA, Rogers S, Caldon CE, Lorca T, Castro A and Burgess A (2014) Partial inhibition of Cdk1 in G2 phase overrides the SAC and decouples mitotic events. *Cell Cycle* **13**, 1400–1412.

27 Li H, Wallerath T and Forstermann U (2002) Physiological mechanisms regulating the expression of endothelial-type NO synthase. *Nitric Oxide* **7**, 132–147.

28 Nussler AK, Gansauge S, Gansauge F, Fischer U, Butzer U, Kremser PG and Beger HG (1998) Overexpression of endothelium-derived nitric oxide synthase isoform 3 in the vasculature of human pancreatic tumor biopsies. *Langenbecks Arch Surg* **383**, 474–480.

29 Ying L and Hofseth LJ (2007) An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. *Cancer Res* **67**, 1407–1410.

30 Song Y, Zhao XP, Song K and Shang ZJ (2013) Ephrin-A1 is up-regulated by hypoxia in cancer cells and promotes angiogenesis of HUVECs through a coordinated cross-talk with eNOS. *PLoS ONE* **8**, e74464.

31 Stephen LJ, Fawkes AL, Verhoeye A, Lemke G and Brown A (2007) A critical role for the EphA3 receptor tyrosine kinase in heart development. *Dev Biol* **302**, 66–79.

32 Su JL, Yang PC, Shih JY, Yang CY, Wei LH, Hsieh CY, Chou JG, Jeng YM, Wang MY, Chang KJ et al. (2006) The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. *Cancer Cell* **9**, 209–223.

33 Punathil T, Tollesbol TO and Katiyar SK (2008) EGCG inhibits mammary cancer cell migration through inhibition of nitric oxide synthase and guanylate cyclase. *Biochem Biophys Res Commun* **375**, 162–167.

34 Yu LB, Dong XS, Sun WZ, Zhao DL and Yang Y (2005) Effect of a nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester on invasion of human colorectal cancer cell line SL-174T. *World J Gastroenterol* **11**, 6385–6388.

35 Hu LD, Zou HF, Zhan SX and Cao KM (2008) EVL (Ea/VASP-like) expression is up-regulated in human breast cancer and its relative expression level is correlated with clinical stages. * Oncol Rep** **19**, 1015–1020.

36 Wu G, Wei L, Yu A, Zhang M, Qi B, Su K, Hu X and Wang J (2011) Vasodilator-stimulated phosphoprotein regulates osteosarcoma cell migration. *Oncol Rep** **26**, 1609–1615.

37 Lee SH, Byun JS, Kong PJ, Lee HJ, Kim DK, Kim HS, Sohn JH, Lee JJ, Lim SY, Chun W et al. (2010) Inhibition of eNOS/sGC/PKG pathway decreases Akt phosphorylation induced by kainic acid in mouse hippocampus. *Korean J Physiol Pharmacol* **14**, 37–43.

38 Xiao H, Zeng L, Shao F, Huang B, Wu M, Tan B and Yin Y (2017) The role of nitric oxide pathway in arginine transport and growth of IPEC-1 cells. *Oncotarget* **8**, 29976–29983.

**Supporting information**

Additional Supporting Information may be found online in the supporting information tab for this article:

**Fig. S1.** Growth inhibitory effect of L-NAME on CCA cell line, KKU-213, and immortalized cholangiocyte cell line, MMNK-1. The cell lines were exposed to L-NAME at different concentrations of between 0.001 and 100 μM. After 48 h, cell proliferation was detected using the sulforonamide B method. Values of percentage cell growth inhibition are expressed as the mean ± SD of three independent experiments.